

The background of the book cover is a high-magnification electron micrograph of a cell nucleus. It shows a large, roughly spherical nucleolus in the center, surrounded by a network of chromatin fibers. The nuclear envelope is visible as a double membrane with nuclear pores. The overall color palette is in shades of orange, red, and brown, with a grainy, high-contrast texture.

# Molecular Biology of Drug Addiction

---

*Edited by*  
**Rafael Maldonado**



**Humana Press**

# Molecular Biology of Drug Addiction

Edited by

**Rafael Maldonado**

*Laboratory of Neuropharmacology  
Health and Life Sciences School  
Universitat Pompeu Fabra  
Barcelona, Spain*

**Humana Press**



**Totowa, New Jersey**


# **Molecular Biology of Drug Addiction**

© 2003 Humana Press Inc.  
999 Riverview Drive, Suite 208  
Totowa, New Jersey 07512  
[www.humanapress.com](http://www.humanapress.com)

All rights reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise without written permission from the Publisher.

The content and opinions expressed in this book are the sole work of the authors and editors, who have warranted due diligence in the creation and issuance of their work. The publisher, editors, and authors are not responsible for errors or omissions or for any consequences arising from the information or opinions presented in this book and make no warranty, express or implied, with respect to its contents.

Due diligence has been taken by the publishers, editors, and authors of this book to assure the accuracy of the information published and to describe generally accepted practices. The contributors herein have carefully checked to ensure that the drug selections and dosages set forth in this text are accurate and in accord with the standards accepted at the time of publication. Notwithstanding, since new research, changes in government regulations, and knowledge from clinical experience relating to drug therapy and drug reactions constantly occur, the reader is advised to check the product information provided by the manufacturer of each drug for any change in dosages or for additional warnings and contraindications. This is of utmost importance when the recommended drug herein is a new or infrequently used drug. It is the responsibility of the treating physician to determine dosages and treatment strategies for individual patients. Further, it is the responsibility of the health care provider to ascertain the Food and Drug Administration status of each drug or device used in their clinical practice. The publishers, editors, and authors are not responsible for errors or omissions or for any consequences from the application of the information presented in this book and make no warranty, express or implied, with respect to the contents in this publication.

This publication is printed on acid-free paper. 

ANSI Z39.48-1984 (American National Standards Institute) Permanence of Paper for Printed Library Materials.

Cover design by Patricia F. Cleary.

Cover illustration: Disruption of the CREB gene in brain by Cre/loxP-mediated recombination (Chapter 2, Fig. 5). See complete illustration on p. 33 and discussion on p. 30.

For additional copies, pricing for bulk purchases, and/or information about other Humana titles, contact Humana at the above address or at any of the following numbers: Tel: 973-256-1699; Fax: 973-256-8341; E-mail: [humana@humanapr.com](mailto:humana@humanapr.com) or visit our website at <http://humanapress.com>

#### **Photocopy Authorization Policy:**

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Humana Press Inc., provided that the base fee of US \$10.00 per copy, plus US \$00.25 per page, is paid directly to the Copyright Clearance Center at 222 Rosewood Drive, Danvers, MA 01923. For those organizations that have been granted a photocopy license from the CCC, a separate system of payment has been arranged and is acceptable to Humana Press Inc. The fee code for users of the Transactional Reporting Service is: [1-58829-060-3/03 \$10.00 + \$00.25].

Printed in the United States of America. 10 9 8 7 6 5 4 3 2 1

#### **Library of Congress Cataloging-in-Publication Data**

Molecular biology of drug addiction / edited by Rafael Maldonado  
p. cm.

Includes bibliographical references and index.

ISBN 1-58829-060-3 (alk. paper)

1. Drug abuse--Molecular aspects. I. Maldonado, Rafael.

RC564 .M638 2003

616.86--dc21

2002024057

## Preface

---

The neurobiological mechanisms involved in drug addiction have been investigated for several decades with a variety of pharmacological and biochemical approaches. These studies have associated several neuroanatomical and neurochemical mechanisms with different components of drug-addictive processes, and this has led to the identification of possible targets for new treatment strategies. Progress has been accelerated dramatically in the last few years by novel research tools that selectively remove or enhance the expression of specific genes encoding proteins responsible for the biological responses of these drugs. These new models, most of them obtained from the recent advances in molecular biology's technology, have provided definitive advances in our understanding of the neurobiological mechanisms of drug addiction. Classical behavioral, biochemical, and anatomical techniques have been adapted to take a maximum advantage of these new molecular tools. These recent studies have clarified the different molecular and intracellular mechanisms involved in addictive processes, as well as the interactions among these endogenous neurobiological mechanisms; and they have provided new insights toward identifying other genetic bases of drug addiction.

The main purpose of *Molecular Biology of Drug Addiction* is to offer an extensive survey of the recent advances in molecular biology and complementary techniques used in the study of the neurobiological basis of drug dependence and addiction. Ours is a multidisciplinary review of the most relevant molecular, genetic, and behavioral approaches used in this field. The definitive advances given by the new molecular and behavioral tools now available provide a unique opportunity for such an approach. Each chapter in this book is not simply a review of the research activities of the author's laboratory, but rather provides a critical review of the main advances in the corresponding topic. Sixteen different chapters organized in four parts have been included in the book. The first part is devoted to the advances in the knowledge of the neurobiological mechanisms of opioid addiction provided in the last few years using the new available techniques, and some of the new therapeutic perspectives now opening up in this field. The second part addresses the most recent findings on the molecular, genetic, and neurochemical mechanisms involved in psychostimulant addiction, which have changed some of the basic knowledge of the neurobiological substrate of these processes. The third part of the book is focused on cannabinoid addiction. New molecular tools have also been used recently to elucidate the biological substrate of cannabinoid dependence. The behavioral models now available, which allow evaluation of the different components of cannabinoid dependence, have



optimized results in this particular field. The last part addresses several molecular, genetic, and behavioral aspects of alcohol and nicotine addiction, which have provided decisive progress in our understanding of these addictive processes.

*Molecular Biology of Drug Addiction* addresses the main advances in understanding the molecular mechanisms involved in the complex physiological and behavioral processes underlying drug addiction and will, we hope, serve as a useful reference guide for a wide range of neuroscientists. This book also provides basic information of interest for scientists and clinicians interested in the new therapeutic approaches to drug addiction. The different sections of the book are presented by the most relevant scientific personalities for each area. I deeply thank the authors for their effort and expert contribution in the different chapters, and Elyse O'Grady at Humana Press for offering this rewarding opportunity. Finally, I thank Raquel Martín especially for help in manuscript preparation and administrative assistance and Dr. Patricia Robledo and Dr. Olga Valverde for scientific assistance and help in library research.

***Rafael Maldonado***

## Contributors

---

- VLADIMIR I. CHEFER • *Integrative Neuroscience Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD*
- JOHN C. CRABBE • *Portland Alcohol Research Center, VA Medical Center and Department of Behavioral Neuroscience, Oregon Health & Science University, Portland, OR*
- CHRISTOPHER L. CUNNINGHAM • *Department of Behavioral Neuroscience and Portland Alcohol Research Center, Oregon Health & Science University, Portland, OR*
- ESTER FRIDE • *Department of Behavioral Sciences, College of Judea and Samaria, Ariel, Israel*
- BRUNO GIROS • *INSERM U513, Faculté de Médecine de Créteil, Créteil, France*
- CHRISTIAN HEIDBREDER • *Biology Department, GlaxoSmithKline Psychiatry CEDD Research Centre, Verona, Italy*
- VOLKER HÖLLT • *Department of Pharmacology, Otto-von-Guericke University, Magdeburg, Germany*
- PETER W. KALIVAS • *Department of Physiology, Medical University of South Carolina, Charleston, SC*
- BRIGITTE L. KIEFFER • *Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS/INSERM/ULP, Illkirch, France*
- THOMAS KOCH • *Department of Pharmacology, Otto-von-Guericke University, Magdeburg, Germany*
- ARON H. LICHTMAN • *Department of Pharmacology and Toxicology, Virginia Commonwealth University Medical College of Virginia, Richmond, VA*
- RAFAEL MALDONADO • *Laboratory of Neuropharmacology, Health and Life Sciences School, Universitat Pompeu Fabra, Barcelona, Spain*
- THEO MANTAMADIOTIS • *Differentiation and Transcription Laboratory, Peter MacCallum Cancer Institute, Vic, Australia*
- MICHELA MARINELLI • *INSERM U259, Université de Bordeaux II, Bordeaux, France*
- BILLY R. MARTIN • *Department of Pharmacology and Toxicology, Virginia Commonwealth University, Medical College of Virginia, Richmond, VA*
- RAPHAEL MECHOULAM • *Department of Medicinal Chemistry and Natural Products, Medical Faculty, Hebrew University of Jerusalem, Jerusalem, Israel*
- LISA M. MONTEGGIA • *Department of Psychiatry, UT Southwestern Medical Center, Dallas, TX*

- MANOLO MUGNAINI • *Biology Department, GlaxoSmithKline Psychiatry CEDD Research Centre, Verona, Italy*
- ERIC J. NESTLER • *Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX*
- FLORENCE NOBLE • *INSERM U266–CNRS UMR 8600, Université René Descartes (Paris V), Paris, France*
- TAMARA J. PHILLIPS • *VA Medical Center, Department of Behavioral Neuroscience and Portland Alcohol Research Center, Oregon Health & Science University, Portland, OR*
- PIER VINCENZO PIAZZA • *INSERM U 259, Université de Bordeaux II, Bordeaux, France*
- EMILIO MERLO PICH • *Investigative Medicine, GlaxoSmithKline Psychiatry CEDD Research Centre, Verona, Italy*
- BERNARD P. ROQUES • *INSERM U266–CNRS UMR 8600, Université René Descartes (Paris V), Paris, France*
- STEFAN SCHULZ • *Department of Pharmacology, Otto-von-Guericke University, Magdeburg, Germany*
- GÜNTHER SCHÜTZ • *Division Molecular Biology of the Cell I, German Cancer Research Center, Heidelberg, Germany*
- DANA E. SELLEY • *Department of Pharmacology and Toxicology, Virginia Commonwealth University Medical College of Virginia, Richmond, VA*
- TONI S. SHIPPENBERG • *Integrative Neuroscience Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD*
- FRÉDÉRIC SIMONIN • *Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS/INSERM/ULP, Illkirch, France*
- RAINER SPANAGEL • *Department of Psychopharmacology, Central Institute of Mental Health, Mannheim, Germany*
- CÉCILE SPIELEWOY • *The Scripps Research Institute, La Jolla, CA*
- VINCENZO TENEGGI • *Investigative Medicine, GlaxoSmithKline Psychiatry CEDD Research Centre, Verona, Italy*



# Contents

---

Preface .....	v
Contributors .....	ix

## PART I. OPIOID ADDICTION

1 Molecular Mechanisms of Opioid Dependence by Using Knockout Mice <i>Brigitte L. Kieffer and Frédéric Simonin</i> .....	3
2 Molecular Genetic Approaches <i>Theo Mantamadiotis, Günther Schütz, and Rafael Maldonado</i> .....	27
3 Opiate Addiction: <i>Role of the cAMP Pathway and CREB</i> <i>Lisa M. Monteggia and Eric J. Nestler</i> .....	37
4 Different Intracellular Signaling Systems Involved in Opioid Tolerance/Dependence <i>Thomas Koch, Stefan Schulz, and Volker Höllt</i> .....	45
5 Inhibitors of Enkephalin Catabolism: <i>New Therapeutic Tool in Opioid Dependence</i> <i>Florence Noble and Bernard P. Roques</i> .....	61

## PART II. PSYCHOSTIMULANT ADDICTION

6 Recent Advances in the Molecular Mechanisms of Psychostimulant Abuse Using Knockout Mice <i>Cécile Spielewoy and Bruno Giros</i> .....	79
7 Opioid Modulation of Psychomotor Stimulant Effects <i>Toni S. Shippenberg and Vladimir I. Chefer</i> .....	107
8 Influence of Environmental and Hormonal Factors in Sensitivity to Psychostimulants <i>Michela Marinelli and Pier Vincenzo Piazza</i> .....	133

- 9 Development and Expression of Behavioral Sensitization:  
*Temporal Profile of Changes in Gene Expression*  
*Peter W. Kalivas* ..... 161

### PART III. CANNABINOID ADDICTION

- 10 New Advances in the Identification and Physiological Roles  
of the Components of the Endogenous Cannabinoid System  
*Ester Fride and Raphael Mechoulam* ..... 173
- 11 Integration of Molecular and Behavioral Approaches  
to Evaluate Cannabinoid Dependence  
*Dana E. Selley, Aron H. Lichtman, and Billy R. Martin* ..... 199
- 12 Opioid System Involvement in Cannabinoid Tolerance  
and Dependence  
*Rafael Maldonado* ..... 221

### PART IV. ALCOHOL AND NICOTINE ADDICTION

- 13 Current Strategies for Identifying Genes for Alcohol Sensitivity  
*John C. Crabbe* ..... 249
- 14 Genetic Basis of Ethanol Reward  
*Christopher L. Cunningham and Tamara J. Phillips* ..... 263
- 15 Behavioral and Molecular Aspects  
of Alcohol Craving and Relapse  
*Rainer Spanagel* ..... 295
- 16 Molecular and Behavioral Aspects of Nicotine Dependence and Reward  
*Emilio Merlo Pich, Christian Heidbreder, Manolo Mugnaini,  
and Vincenzo Teneggi* ..... 315
- Index ..... 339

# **PART I**

## **OPIOID ADDICTION**



## Molecular Mechanisms of Opioid Dependence by Using Knockout Mice

---

Brigitte L. Kieffer and Frédéric Simonin

---

### 1. Introduction

Opium, extracted from the seed of the poppy *Papaver somniferum*, has been used and abused for several thousand years. This substance is highly efficient to relieve pain or treat dysentery, and also shows strong euphoric and addictive properties. Due to their exceptional therapeutic potential, the active ingredients of opium have been the subject of intense investigations. Morphine, named after Morpheus, the Greek god of dreams, was isolated in 1806 (1) and is considered the prototypic opioid compound. This compound retains both analgesic and addictive properties of opium. Despite numerous adverse effects (2), morphine remains the best painkiller in contemporary medicine, and its clinical use is under tight regulation. In 1898 heroin was chemically synthesized by morphine diacetylation, in an attempt to obtain a drug with lower abuse liability. In fact, this morphine derivative showed even higher addictive potential due to its distinct pharmacokinetic properties. Heroin is being illegally abused worldwide and represents a major public health problem. Attempts to dissociate opioid analgesia from opioid addiction have been unsuccessful so far.

Opioids have been classified as narcotic drugs (from the Greek word for stupor), due to their pharmacological profile very distinct from that of other drugs of abuse, such as psychostimulants (cocaine, amphetamine), cannabinoids, nicotine, or alcohol (3). As for other substances of abuse, though, opioid addiction typically develops in four stages (4): (a) the initiation phase, in which drug exposure produces positive subjective effects (euphoria); (b) the maintenance phase, in which drug-taking becomes compulsive, indicating that dependence has developed; (c) withdrawal, which develops when drug levels decrease in the body and is recurrently experienced by drug abusers; and (d) craving—or the intense desire to use the drug—and relapse, which are most critical from a therapeutic standpoint. Not every individual exposed to opioids will develop addiction, depending on social, contextual, or perhaps genetic factors (5). However, opioids are considered strongly addictive, and it has been proposed that incremental—perhaps irreversible—neuroadaptations profoundly modify the central nervous system (CNS) following repeated opioid exposure, and contribute to the establishment of opioid dependence (6).

Opioid addiction is a complex phenomenon. Opioid drugs act by activating opioid receptors distributed throughout the CNS and stimulate a number of pathways, among

From: *Molecular Biology of Drug Addiction*  
Edited by: R. Maldonado © Humana Press Inc., Totowa, NJ

which the so-called reward pathways located in the limbic system (7) are particularly relevant to the addictive process. Repeated opioid stimulation will modify and dysregulate opioid receptor activity and, consequently, interfere with a tightly regulated endogenous opioid system (8), which is critically involved in the control of natural rewards and motivation (7,9), as well as responses to stress (10) and pain (11). The endogenous opioid system itself interacts with other neurotransmitter systems, and long-term exposure to exogenous opioids may ultimately remodel associated neuronal networks within brain circuits (12) and activate antiopioid systems that counteract opioid effects (13–15), thereby modifying hedonic homeostasis (16).

Recent research aims at clarifying the molecular mechanisms of neuroadaptations to chronic opioids. Cellular models have highlighted regulatory processes, which occur at the level of opioid receptors and their associated signaling proteins, and are believed to contribute to the development of opioid tolerance and withdrawal. Receptor uncoupling from second messenger systems, receptor downregulation, and adenylyl cyclase upregulation were largely shown in neuroblastoma cells expressing opioid receptors endogenously (17). Agonist-induced receptor phosphorylation, desensitization, internalisation, and trafficking were demonstrated more recently using recombinant opioid receptors (e.g., 18–24). These studies, however, addressed a limited aspect of opioid adaptations, and the link between early agonist-induced events and integrated behavioral responses remains to be established. In vivo, biochemical studies have confirmed upregulation of the cAMP pathway in several brain areas, shown modifications of tyrosine hydroxylase, glutamate receptor subunits, or cytoskeleton protein levels, and proposed a role for growth and transcription factors in the establishment of opioid addiction (6,25).

Gene manipulation in rodents provides a unique mean to correlate molecular events with complex behavior, and is now used to study substance abuse. Possible approaches include (a) targeted gene inactivation using homologous recombination in embryonic stem cells (knockouts), (b) gene overexpression by egg microinjection (transgenics), (c) gene overexpression by viral-mediated gene transfer in adult mice, and (d) gene downregulation by antisense oligonucleotides (26). In this chapter we will focus on gene knockout models, in an attempt to analyze what these unique genetic tools have taught us about opioid addiction. Recently, a number of null mutant mice have been subjected to chronic morphine treatments and their responses found to differ from their wild-type controls (*see* Tables 1–3). These observations have highlighted a role for a number of known genes in behavioral responses to opioids, and allow us to establish a connection between the activity of these genes and molecular neuroadaptations subsequent to chronic opioid treatments in vivo.

## 2. The Behavioral Models

The manifestations of opioid addiction and dependence can be evaluated in mice using a large panel of behavioral models (27). The reinforcing properties of opioids are currently investigated using conditioned place preference (CPP) or self-administration (SA) procedures. The development of tolerance is observed at the level of opioid analgesia. Typically, tail withdrawal latencies are measured in response to thermal or mechanical pain (tail flick, tail immersion, tail pinch, or hot plate). Latencies are prolonged following acute treatment (analgesia) and gradually return to control values under



**Table 1**  
**Effects of Morphine in Knockout Mice of the Opioid System<sup>a</sup>**

Gene knockout	Acute morphine	Tolerance to analgesia	Morphine reward	Morphine withdrawal	Reference
MOR	Analgesia abolished		CPP abolished	Somatic and vegetative signs absent	28
	Hyperlocomotion abolished		SA below saline		29 30
DOR	Analgesia unchanged	Abolished (TF)		Somatic signs unchanged	31 Pintar J., personal communication
KOR	Analgesia unchanged		CPP unchanged	Somatic signs reduced	32
PreproENK		Abolished (TF)		Somatic signs unchanged	31 Pintar J., personal communication

<sup>a</sup>CPP, conditioned place preference; SA, self-administration; TF, tail-flick.

**Table 2**  
**Effects of Morphine in Knockout Mice for Neuropeptides and Receptors<sup>a</sup>**

Gene knockout	Acute morphine	Tolerance to analgesia	Sensitization to hyperlocomotion	Morphine reward	Morphine withdrawal	Reference
CB1	Analgesia unchanged	Unchanged (HP, TI)		SA abolished	Somatic signs reduced	33
				DA increase in Nuc Acc		34
				abolished		
	Hyperlocomotion unchanged		Abolished	CPP abolished	Withdrawal CPA unchanged	35
				SA abolished	Somatic signs reduced	36
						37
D2R	Analgesia unchanged; hyperlocomotion unchanged			CPP abolished	Somatic signs unchanged	38
				CPP maintained in naive but absent during withdrawal	Somatic signs unchanged; withdrawal CPA abolished	39
DAT	Analgesia unchanged; hyperlocomotion abolished			CPP enhanced	Some somatic signs reduced (but not jump)	40

NK1	Analgesia unchanged; hyperlocomotion abolished	CPP abolished	Jump abolished; other somatic signs unchanged; withdrawal CPA reduced	41
GluR-A and GluR-A(R/R) <sup>b</sup>	Analgesia unchanged; hyperlocomotion unchanged	Abolished in GluR-A; unchanged in GluR- A(R/R) (TF)	Context- independent sensitization abolished	42
OFQ/N	Analgesia unchanged	Unchanged (TI)	Jump increased	43
ORL-1	Analgesia unchanged Analgesia unchanged	Reduced (TP) Reduced (TP and TF)	Jump reduced; other somatic signs abolished	44 45
$\alpha$ CGRP	Analgesia reduced; SIA abolished	Unchanged (TF)	Heroin SA unchanged	46
IL6	Analgesia reduced; SIA abolished	Faster (HP)	Somatic signs reduced	47

<sup>a</sup>CPA, conditioned place aversion; CPP, conditioned place preference; DA, dopamine; HP, hot plate; Nuc Acc, nucleus accumbens; SA, self-administration; SIA, stress-induced analgesia; TF, tail flick; TI, tail immersion; TP, tail pinch.

<sup>b</sup>In GluR-A(R/R) mutant mice the Q582 residue of the GluR-A subunit is replaced by an arginine residue, which reduces the calcium permeability and channel conductance of receptors containing this subunit.